CTIC CTI BioPharma Corp.

1.25
-0.12  -8%
Previous Close 1.36
Open 1.4
Price To Book 1.26
Market Cap 72195760
Shares 57,988,562
Volume 397,440
Short Ratio
Av. Daily Volume 178,212

SEC filingsSee all SEC filings

  1. 8-K - Current report 181233904
  2. 8-K - Current report 181201350
  3. 8-K - Current report 181154176
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181154128
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181153624

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released July 9. 2018. Primary endpoint not met.
PIXUVRI - PIX306 Trial
B-cell non-Hodgkin lymphoma
Phase 2 enrollment to be completed by end of 2018 with top-line data due 2Q 2019. Interim safety review 1Q 2019.
Pacritinib - PAC203
Myelofibrosis
Phase 3 trial potentially in the pipeline.
Tosedostat
Older patients with AML or high-risk myelodysplastic syndrome (MDS) - cancer
Phase 3 - noted July 2016 that unlikely to have survival benefit
OPAXIO
Ovarian cancer

SEC Filings

  1. 8-K - Current report 181233904
  2. 8-K - Current report 181201350
  3. 8-K - Current report 181154176
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181154128
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181153624
  6. 8-K - Current report 181152133
  7. 8-K - Current report 181082470
  8. 8-K - Current report 181056516
  9. 8-K - Current report 181019327
  10. 8-K - Current report 18989827